Potential clinical applications of vasoactive intestinal peptide: A selected update

Illana Gozes*, Sharon Furman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Neuropeptides are expressed in neurons innervating endocrine cells or in endocrine cells and cancer cells, and are released on site to act as hormones and growth factors. Vasoactive intestinal peptide (VIP) was first discovered in the early 1970s and has since become the area of research for many laboratories. VIP has a neuroendocrine role as it is intimately involved with the synthesis, secretion and action of other neuroendocrine hormones as well as cytokines and chemokines. Major outcomes of VIP downregulation encompass developmental and behavioral dysfunctions, including impaired diurnal rhythms. Overexpression of VIP has been associated with diarrhea and cancer, and overexpression of VIP receptors is associated with cancerous growth. This short review outlines some of the recent progress made in VIP research.

Original languageEnglish
Pages (from-to)623-640
Number of pages18
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume18
Issue number4
DOIs
StatePublished - Dec 2004

Keywords

  • PAC1
  • VIP
  • VIP analogs
  • VPAC1
  • VPAC2

Fingerprint

Dive into the research topics of 'Potential clinical applications of vasoactive intestinal peptide: A selected update'. Together they form a unique fingerprint.

Cite this